Have a feature idea you'd love to see implemented?
Let us know!
OCX OncoCyte Corp
Price (delayed)
$2.67
Market cap
$44.95M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$18,083.2
Enterprise value
$43.88M
Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum. The Company, through its proprietary tests and pharmaceutical
Highlights
OncoCyte's net income has increased by 24% YoY but it has decreased by 19% QoQ
OCX's gross margin has dropped by 147% year-on-year
OncoCyte's gross profit has shrunk by 123% YoY
Key stats
What are the main financial stats of OCX
Market
Valuations
Earnings
Shares outstanding
16.84M
Market cap
$44.95M
Enterprise value
$43.88M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.68
Price to sales (P/S)
51.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
61.89
Revenue
$709,000
EBIT
-$43.14M
EBITDA
-$41.81M
Free cash flow
-$20.49M
Per share
Balance sheet
Liquidity
EPS
-$18,083.2
Free cash flow per share
-$1.49
Book value per share
$0.73
Revenue per share
$0.05
TBVPS
$1
Total assets
$70.22M
Total liabilities
$60.51M
Debt
$3.99M
Equity
$9.71M
Working capital
-$4.3M
Debt to equity
0.41
Current ratio
0.53
Quick ratio
0.58
Net debt/EBITDA
0.03
Margins
Efficiency
Dividend
EBITDA margin
-5,897%
Gross margin
-16.2%
Net margin
-6,114.2%
Operating margin
-6,148.5%
Return on assets
-59.9%
Return on equity
-270.2%
Return on invested capital
-1,464.2%
Return on capital employed
-70.6%
Return on sales
-6,084.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OCX stock price
How has the OncoCyte stock price performed over time
Intraday
-2.91%
1 week
-4.64%
1 month
-14.42%
1 year
-33.08%
YTD
6.8%
QTD
-6.32%
Financial performance
How have OncoCyte's revenue and profit performed over time
Revenue
$709,000
Gross profit
-$115,000
Operating income
-$43.59M
Net income
-$43.35M
Gross margin
-16.2%
Net margin
-6,114.2%
OCX's gross margin has dropped by 147% year-on-year
OncoCyte's gross profit has shrunk by 123% YoY
The operating income has dropped by 112% year-on-year and by 19% since the previous quarter
OCX's net margin has dropped by 72% since the previous quarter and by 56% year-on-year
Growth
What is OncoCyte's growth rate over time
Valuation
What is OncoCyte stock price valuation
P/E
N/A
P/B
3.68
P/S
51.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
61.89
The company's EPS has shrunk by 60% QoQ and by 18% YoY
OncoCyte's equity has shrunk by 74% YoY and by 57% QoQ
The stock's price to book (P/B) is 67% more than its last 4 quarters average of 2.2 and 42% more than its 5-year quarterly average of 2.6
The price to sales (P/S) is 92% less than the 5-year quarterly average of 663.5 but 69% more than the last 4 quarters average of 30.6
The revenue has shrunk by 52% YoY and by 31% QoQ
Efficiency
How efficient is OncoCyte business performance
The company's return on equity has shrunk by 80% YoY and by 71% QoQ
The company's return on sales has shrunk by 72% QoQ and by 55% YoY
OCX's ROIC has dropped by 70% year-on-year and by 29% since the previous quarter
OCX's return on assets is down by 24% since the previous quarter but it is up by 9% year-on-year
Dividends
What is OCX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OCX.
Financial health
How did OncoCyte financials performed over time
OCX's total assets is 16% greater than its total liabilities
The current ratio has plunged by 75% YoY and by 62% from the previous quarter
OCX's quick ratio has dropped by 74% year-on-year and by 62% since the previous quarter
OCX's debt is 59% smaller than its equity
The debt to equity has surged by 156% since the previous quarter
OncoCyte's equity has shrunk by 74% YoY and by 57% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.